Alpelisib, the pioneering PI3Kα inhibitor used for breast cancer treatment, has extended progression-free survival in patients with HR+/HER2- metastatic breast cancer carrying PIK3CA mutations when combined with Fulvestrant (NCT02437318) (137). This evidence concerns the gene PIK3CA and breast carcinoma.